European Paediatric Formulation Initiative in partnership with International Association for Pharmaceutical Technology.
UNIVERSITY OF WARSAW Krakowskie Przedmieście 26/28 00-927 Warsaw, Poland Phone: (+48) 22 55 20 000
|March 20th, 2017||Preliminary programme announcement|
|July 20th,2017||Second announcement|
|March 25th,2017||On-line registration and abstract submission open|
|May 30th,2017||Abstract submission deadline|
|July 3rd,2017||Notification about abstract acceptance (preliminary date)|
September 20 to 21st nd,2017
Preconference workshop - 19th September 2017
- Abstract Topics
- Responsibilities of the Presenting Author
- Author's Consent and Waiver of Claims
- General Guidelines
- Preferred Presentation Format
- Requesting Special Consideration
- Abstract Review and Selection Process
- Acceptance/Rejection Notification
- Abstract Withdrawal
- Publication in the EuPFI Special Issue
- Late-Breaking Abstracts
- Abstract Submission Policies
- How to Submit an Abstract
- Preparing an Abstract for Submission
- PCCA Awards
- Abstract Template
- Contact Information
- Age appropriateness of formulation/compliance-adherence issues
- Administration devices
- Developing paediatric drug formulations
- Formulating paediatric medicines for developing countries
- Lessons learned from PIP submissions
- Taste Assessment and Taste Masking
- Research and/or studies must fit into one of the EuPFI abstract topics listed above
- Data already published by August Sept 15 either online or in print, data presented at a national or international meeting will generally not be eligible for consideration. We encourage the authors to request special consideration (see section below) if the abstract is a minor extension of published work.
- The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Presenter Information” section of the online abstract submission system.
- The presenting author must be one of the co-authors listed on the submitted abstract.
- The presenting author is responsible for the following:
- Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
- Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by EuPFI.
- Obtaining all of the conflict-of-interest disclosure and copyright transfer information from co-authors.
- Forwarding all correspondence to all co-authors, including EuPFI submission guidelines and reviewers comments.
- Each abstract author agrees and certifies that he or she:
- has read all of the rules and agrees to be bound by them,
- is responsible for submission of the abstract in accordance with the rules, and
- waives any and all claims against EuPFI and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
- The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
- Abstracts submitted to EuPFI 2017 are embargoed from the time of submission. This means that the data in the abstract cannot be submitted to other meetings and/or publishers once submitted for the EuPFI conference.
- No revisions can be made after the abstract submission deadline.
- Abstracts generally may not be withdrawn once submitted. If you prefer that your abstract be withdrawn if not accepted for any presentation at the EuPFI conference, you must indicate so during online submission.
- The presentation at the EuPFI conference must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the conference must match the submitted abstract, although updates on results may be added.
- Abstracts should be written in clear and concise English, so that reviewers are able to focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.
- Authors should select whether they prefer oral or poster presentation. Abstracts noted with a preference for poster presentation will NOT be considered for oral presentation, regardless of score.
- Second, in the event that an abstract is not chosen for oral presentation, it can still be chosen for poster presentation. Authors who state a preference for oral presentation must decide whether they would accept poster presentation. Authors may either present a poster or request that the abstract be immediately withdrawn. (Please note that declining to have your abstract considered for poster presentation does not improve its chances of being accepted as an oral presentation. This option should be selected primarily by authors who would not be willing to present a poster.)
- Finally, in the event the abstract is NOT selected for presentation, all submitting authors must decide whether they want their abstract to be published in the EuPFI special issue in International Journal of Pharmaceutics or whether the abstract should be withdrawn completely and not published either online or in print.
- Special consideration may be requested by explaining the special circumstances in the text box provided during the online abstract submission process. We encourage authors to request special consideration if the abstract is a minor extension of previously published work or if the author has a reason to believe that the data will be published, either online or in print, or presented in any form prior to the conference. The information provided will be carefully evaluated by the reviewers.
- Failure of authors to request special consideration for an abstract, including content that has been published or presented at a major national or international meeting (‘major’ is defined as 1,000 or more attendees) or in a press release published before the EuPFI conference, will result in exclusion from the program.
- After the submission deadline, all completed and eligible abstracts will be made available to the reviewing committee for blinded review and scoring, and final decisions will be made by the Program Committee in late June 2017.
- Abstracts will be evaluated and scored solely on their scientific merits.
- Incomplete abstracts will not be reviewed.
- The same study must not be submitted as multiple abstracts. Abstracts that are simply different versions of a single study will be rejected.
- Abstracts will be peer reviewed according to the topics. Authors must indicate during online submission the appropriate review category (one only). Please select the topic that is most closely associated with your abstract.
- All abstracts submitted will be considered eligible for one presentation: either oral (Soapbox session), or poster
- Oral (soapbox) Sessions are formal 12 minutes oral presentations followed by a 3 min Q&A.
- Poster Sessions allow the viewing of a poster illustration of the abstract. Authors are expected to post and remove posters at designated times and to be at their posters to answer questions during the time designated for poster presentations. The author’s attendance during poster presentation time will be monitored.
- Notification regarding acceptance or rejection of abstracts will be sent to the presenting author by 3rd July 2017 by email; consequently, an accurate email address is critical. If your abstract is accepted, the e-mail will specify whether it is accepted as oral, or poster presentation. If you have not received an email notification by July 10, 2017, contact email@example.com. Rejection notifications will also be sent at that time.
- To ensure that you are able to receive email correspondence from EuPFI, please make sure that you use your email as the username while registering to the abstracts submission system. If after completing your submission you don't receive a confirmation email from the abstract system within three working days, you must contact EuPFI at firstname.lastname@example.org
- The decision of the EuPFI conference committee regarding acceptance and presentation of abstracts is final.
- Once an abstract is accepted, a written request to withdraw must be submitted no later than Sept 12th, 2017 to email@example.com. If the first author decides to withdraw the abstract for any reason. Abstract withdrawal requests received after the deadline will be considered on a case-by-case basis.
- EuPFI reserves the right to withdraw abstracts that are not as per the submission guidelines, such as those that have been previously published or presented, have been deemed scientifically unsound, or have been found to include inaccurate data, etc.
- If you indicated at submission that you wish to withdraw your abstract if it is not accepted for either oral or poster presentation, your abstract will be automatically withdrawn, and you will be notified; you do not need to request withdrawal.
- All abstracts accepted for presentation (oral, or poster) at the EuPFI 2017 conference will be published in a special issue of EuPFI in international Journal of Pharmaceutics
- If an author does not want the abstract published, he/she must indicate that during submission.
- EuPFI reserves the right not to publish abstracts that do not fit into any of the topics, abstracts that inappropriately promote commercial interests, abstracts that are judged unethical, poorly written, or scientifically unsound, or abstracts considered inappropriate for publication for other reasons as determined by the Program Committee.
Recognising that the results of some top-quality research may not be available by the general abstract submission deadline, the EuPFI Program Committee offers an option for late-breaking abstracts. Late-breaking abstracts will undergo regular peer-review evaluation. The accepted abstracts will be published. Late-breaking abstracts will not be considered for oral presentations but only for poster presentation.back to top
- The presenting author is responsible for obtaining disclosure information from all co-authors.
- All authors and co-authors are required to provide any relevant information concerning personal or professional circumstances and relationships that might reasonably be expected to affect the author’s view on the presentation.
- This includes relationships with pharmaceutical companies, biomedical device manufacturers, or other companies whose products or services are related to the subject matter of the presentation topic. If no relevant relationships exist, this must be stated as well.
abstract submission site is open March 25th - May 30th, 2017. All abstracts must be submitted by deadline May 30th, 2017, at 11:59 p.m., BST. Submissions that are incomplete by the deadline will be rejected.
- Abstracts must be submitted online through the official online abstract submission site. E-mails and word processing files not submitted through the site will not be accepted.
- Once you have submitted the title page information, a draft of your abstract will be saved, and you will be able to return to edit and update it at any time until August 14, 2017, at 11:59 p.m., PDT. You will receive an e-mail providing a link to your submission.
- Abstracts cannot be submitted and will not be reviewed without proper payment and completion of the “Submission Information” and “Disclosure” sections of the online abstract submission program.
Any technical questions regarding the submission process should be directed to firstname.lastname@example.org to top
Dos and Don'ts
- Your name, degree, institution, address, phone number, and e-mail address must be provided. As the corresponding author, you will receive all future correspondence from EuPFI.
- Please underline the name of the author who will present the abstract. Ideally, the corresponding author should be the first author (presenter) of the abstract, unless otherwise noted during submission.
- Names of co-authors and institutions must be provided. Changes will not be made to the spelling of authors’ names after the submission deadline; please proof your co-authors’ names carefully.
- The abstract title should be brief and clearly indicate the nature of the abstract.
- The abstract title must be in sentence case and bold.
- Additionally, keep letters lowercase if the lowercase letters have a specific meaning, such as pH or NaCl.
- Do not put a period at the end of the title.
- Non-proprietary (generic/scientific) names should be used and should be lowercase.
- If necessary, you may include a proprietary name in parentheses directly following the generic name after its first mention in the body of the abstract; the first letter of the name of a proprietary drug should be capitalised. EuPFI reserves the right to replace proprietary names with generic names to adhere to this policy.
- Use standard abbreviations. Place abbreviations in parentheses immediately after the first mention of a term or phrase; the abbreviation can then be used throughout the abstract.
- Abstracts accepted for the EuPFI 2017 will be published in a EuPFI special . Abstracts will be typeset from the text submitted by the author without copyediting changes. It is the responsibility of the author to proofread the abstract carefully.
- There is no limit on word or characters of the abstract. However the entire body of the abstract, including title, authors, text and tables, must not exceed one A4 size page.
- The abstract should be structured (i.e., divided into sections using terms such as Introduction, Methods, Results, Conclusions, etc.) .
- Do not use bold type or underline formatting for the body of the abstract. Italic type is acceptable. Only the Title and Authors must be bold.
- Text may be in multiple paragraphs. Do not indent the first line of paragraphs.
- Special Greek and mathematical symbols are available in a character map within the submission system.
- Use numerals to indicate numbers, except when beginning sentences.
- Simple tables and graphs may be included.
- Any references should be noted as citations within the text and not as footnotes at the end.
- Be sure to select from the topics that best describes your abstract. Note that the abstract will be reviewed in the topic you selected.
back to top
Number Offered: Four awards of Euros 250 each for the best 3 poster presentations and 1 oral presentation made by a student at the EuPFI Annual Conference.
Application Closing Date: Abstract accepted. The participants can raise the interest at the time of submission of abstract. Click on button ‘would like to participate in PCCA award’ during the submission of abstract. Additionally, the eligible poster author who wish to be considered for the “Best Student Poster Award” can place a sticker (provided at registration) on their board indicating their interest at the beginning of the conference.
How to be considered for an Abstract Achievement Award:
- Eligible poster author who wish to be considered for the “Best Student Poster Award” have to place a sticker (provided at registration) on their board indicating their interest at the beginning of the conference.
- Submit the pdf copy of poster by 10th Sept 2017 to email@example.com, if you have registered the interest while submission. For the participants who intend to register interest during the day, please bring pdf copies of your poster for judges.
- All eligible posters will be on display throughout the event and lead authors will be required to be present to answer questions about their posters at set times during the event i.e the authors with odd number poster ID must be present by their posters at 10:45 - 11:00am on 20th Sept and the authors with even numbers poster ID must be present at 15:45 - 16:00pm on 20th Sept
- The best posters should make a significant contribution towards improving identified issues and challenges associated with development of paediatric formulation, to ultimately raise awareness and consider ways towards better medications and clinically relevant dosage forms for children. Award Criteria
- The applicant must be the presenting, and thus first named, author of the abstract.
- The abstract must be the only one submitted by the applicant for that award. Only one award per student.
- The abstract must not be entered for consideration for any other Annual Conference awards.
- The work presented must have been completed as part of a first degree, a taught Masters degree or a postgraduate qualification (PhD). Work must be presented within 12-months of completion of the degree. Post-doctoral fellows are not eligible.
- The awards will be given for excellence, reflected in the content, presentation and defence quality of the poster.
- The Awards Panel's decision is final in all cases. The panel is composed of PCCA and EuPFI representatives.
- After the meeting, “electronic” versions of the winning posters will be posted on EuPFI and PCCA websites.
- About the SponsorProfessional Compounding Centers of America (PCCA) is a multinational company dedicated to the advancement of pharmaceutical compounding through its over 4,000 members worldwide. For more than 30 years, PCCA has been a leading resource for the highest quality raw materials; innovative bases, equipment and devices; compounding pharmacy software; specialised consultancy services and accredited education and training. PCCA’s mission is to strengthen the role, position and skills of member pharmacists so they can meet the unique healthcare needs of patients through compounded medications.http://www.pccarx.com/what-is-compounding/specialty-compounding/pediatric-compounding
Abstract Achievement Award Notifications:
Abstract Achievement Award recipients will be notified and will receive an award on day two of the conference i.e 21st Sept 2017.back to top
back to top
All participants are kindly recommended to register via Online Registration Form on APV website. Please fax this document to APV Headquarters: 0049 6131 9769-69 or send it via email to firstname.lastname@example.org. Please read the instructions on the APV website carefully.
To benefit from the reduced early registration fee, please process your registration before July 15th,2017.
Upon submitting the Registration Form, You will receive a confirmation by e-mail of your registration with the invoice.
All participants are kindly requested to register in advance by completing and submitting the Registration Form with the appropriate fees.
Please note unpaid pre-registration will not be considered as a valid registration unless fully paid and confirmed. Pre-registration summary therefore cannot be taken as a valid registration confirmation. Please make sure to pay your registration fee within the time frame for early or regular registration.
Students have to submit a copy of their student ID to the Conference email/contact address or fax number. Please note that if we do not receive this certification within 7 days after your data submission your registration will not be considered as valid.
*Early Bird Deadline is 15th July 2017
Delegate registration fee includes
- Admission to scientific sessions, exhibition and poster area
- Conference materials
- Coffee breaks
- Conference Dinner & Social Programme
The registration fees do not include insurance of participants against accidents, sickness, cancellation, theft, property damage or loss. Participants are advised to take out adequate personal insurance.
Upon receipt of the correct registration fee (clear of bank charges), each participant will receive a confirmation of registration. Please bring this confirmation to the Registration desk at the conference venue as proof of your registration. Confirmation will be sent upon receipt of payment.
All fees for the Conference registration should be paid in EUR (€), free of all bank charges.
- credit card payment (Visa, Eurocard/Mastercard)
- by bank transfer
Cancellation / Refund Policy
We would like to point out that participation can be cancelled free of charge within two weeks of registration via the web.
Publication in the list of participants
In case you wish not to include your name and email address in the list of participants please send email to the Conference secretariat.
The participant acknowledges that he/she has no right to lodge damage claims against the organisers should the holding of the Conference be hindered or prevented by unexpected political or economic events or generally by force majeure, or should the non-appearance of speakers or other reasons necessitate programme changes. With registration, the participant accepts this proviso.
Information to be available soon
Exhibition and Sponsorship
We are glad to tailor a sponsor package (starting from 1000 EUR) according to your wishes.
For general information, Click here
As an exhibitor you will be also invited to attend the sessions and network at the Networking Dinner in the evening. At the conference center the poster presentations will again be integrated in the exhibition, ensuring that participants are around the exhibition stands as much as possible. Price for a tabletop space with table, chairs and power supply is 990 EUR plus one mandatory full conference registration (register before July 15, to take advantage of the early bird fee!).
For details regarding sponsorship and exhibition opportunities, please contact
Phone: ++49 6131 9769-90
We look forward to seeing you in Warsaw!
8th Conference of the European Paediatric Formulation Initiative
International Association for Pharmaceutical Technology
Kurfürstenstraße 59, 55118 Mainz/Germany
European Paediatric Formulation Initiative
Website: www.eupfi.orgE-mail: email@example.com
University College London School of Pharmacy, 29-39, Brunswick Square London , WC1N 1AX Phone: 0044 20 7753 5846 Fax: 0044 20 7753 5942 ;